185955-34-4

Basic information

• Product Name: Eritoran
• Synonyms: Eritoran [inn];E5564;ERITORAN;3-O-Decyl-2-deoxy-6-O-[2-deoxy-3-O-[(3R)-3-methoxydecyl]-6-O-methyl-2-[[(11Z)-1-oxo-11-octadecenyl]amino]-4-O-phosphono-beta-D-glucopyranosyl]-2-[(1,3-dioxotetradecyl)amino]-alpha-D-glucopyranose 1-(dihydrogen phosphate)
• CAS NO: 185955-34-4
• Molecular Formula: C66H122N2O19P2.4Na
• Molecular Weight: 1401.59
• Mol File: 185955-34-4.mol
• Article Data: 0

Chemical Properties

• Appearance: /
• Density: 1.14
• PKA: 1.73±0.10(Predicted)
• CAS DataBase Reference: Eritoran(CAS DataBase Reference)
• NIST Chemistry Reference: Eritoran(185955-34-4)
• EPA Substance Registry System: Eritoran(185955-34-4)

Safety Data

• Hazardous Substances Data: 185955-34-4(Hazardous Substances Data)

Usage

Description

Eritoran, also known as E5564, is a small molecule that acts as a selective antagonist of the Toll-like receptor 4 (TLR4). It is derived from the natural product eritadenine and has been developed for its potential therapeutic applications in various medical conditions. Eritoran possesses the ability to modulate the immune response by blocking the TLR4 signaling pathway, which plays a crucial role in the recognition of bacterial endotoxins and the subsequent activation of the immune system.

Uses

Used in Pharmaceutical Industry:
Eritoran is used as an endotoxin antagonist for the treatment of sepsis and other diseases caused by the reaction to bacterial endotoxins. By selectively blocking the TLR4 receptor, Eritoran can potentially reduce the severity of the immune response and alleviate the symptoms associated with these conditions.
Used in Clinical Trials:
Eritoran has been investigated in clinical trials for its potential use in treating severe sepsis and septic shock. The trials aim to evaluate the safety, tolerability, and efficacy of Eritoran in reducing the mortality and morbidity associated with these life-threatening conditions.
Used in Research Applications:
Eritoran is also used as a research tool to study the role of TLR4 in various immune-mediated diseases and to understand the underlying mechanisms of the immune response to bacterial endotoxins. This knowledge can contribute to the development of novel therapeutic strategies for a wide range of conditions, including autoimmune disorders and chronic inflammatory diseases.

InChI:InChI=1/C66H126N2O19P2.4Na/c1-7-11-15-19-22-25-26-27-28-29-30-32-34-38-42-46-57(70)67-60-64(82-49-47-54(80-6)45-41-36-18-14-10-4)62(86-88(73,74)75)56(51-79-5)85-65(60)83-52-55-61(72)63(81-48-43-39-35-24-21-17-13-9-3)59(66(84-55)87-89(76,77)78)68-58(71)50-53(69)44-40-37-33-31-23-20-16-12-8-2;;;;/h25-26,54-56,59-66,72H,7-24,27-52H2,1-6H3,(H,67,70)(H,68,71)(H2,73,74,75)(H2,76,77,78);;;;/q;4*+1/p-4/b26-25-;;;;/t54-,55-,56-,59-,60-,61-,62-,63-,64-,65-,66-;;;;/m1..../s1